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Abstract
Laminin levels in ascitic fluid have been proposed as a marker for
neoplastic ascites. We compared the concentration of laminin in
serum and in ascitic fluid from patients with hepatic cirrhosis and
peritoneal carcinomatosis and assessed the diagnostic value of serum
laminin levels in differentiating neoplastic from benign ascites. Lam-
inin concentrations were determined by ELISA with antibodies against
laminin extracted from the human placenta, in patients with ascites
due to peritoneal carcinomatosis (N = 20) and hepatic cirrhosis (N =
33). Patients with infected or hemorrhagic ascites were excluded. The
receiver operating characteristic curve was used to determine the
sensitivity and specificity of serum laminin for the diagnosis of
neoplastic ascites. When compared to the group with cirrhosis, the
carcinomatosis group presented significantly higher mean laminin
levels in serum (3.3 ± 0.5 vs 2.1 ± 0.4 µg/ml, mean ± SD, P < 0.05) and
ascites (2.8 ± 0.5 vs 1.6 ± 0.4 µg/ml, P < 0.05). Although laminin
concentration was higher in serum than in ascites, the laminin serum/
ascites ratio and serum-ascites gradient did not differ between the
studied groups. A significant correlation (r = 0.93, P < 0.0001) was
observed between the serum and ascites laminin values. Serum lami-
nin levels >2.25 µg/ml showed 100% sensitivity and 73% specificity
for the diagnosis of neoplastic ascites. Serum concentration seems to
be the main determinant of laminin levels in ascitic fluid and its values
can be used as a diagnostic parameter in the study of neoplastic ascites.
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Introduction
Laminin, a basement membrane glyco-
protein, participates in a series of biological
phenomena such as adhesion, migration, dif-
ferentiation, and cell growth (1), in addition
to the maintenance of essential membrane
architecture (2,3). Its serum levels have been
studied in patients with portal hypertension
and neoplastic diseases.
Increased serum laminin levels have been
observed in chronic liver diseases with fibro-
sis and/or liver cirrhosis and can be corre-
lated with portal pressure levels (4-6) and
with the functional status of the liver (6,7).
The increase in circulating glycoprotein has
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been attributed to a progressive increase in
laminin deposition along the sinusoids dur-
ing capillarization of the Disse’s space (4,8,
9). Furthermore, increased serum laminin
levels are also found in patients with neo-
plasms, especially in cases of basement mem-
brane alterations associated with tumor pro-
liferation and invasion (10,11). The serum
values tend to increase significantly with the
emergence of metastases, independent of
tumor lineage or neoplasm origin (12-15).
The levels of laminin in ascitic fluid have
also been proposed as a neoplastic ascites
marker (16), but no systematic study has
been reported in the literature.
Patients and Methods
Twenty-five healthy adult individuals, 10
men and 15 women, with a mean age of 44 ±
15 years (mean ± SD) were studied as a
reference population for the quantification
of serum laminin (control group).
An additional group of 53 patients (18 to
74 years old), mainly Caucasians (93%),
was included in the study and divided into:
Group 1. Thirty-three patients with liver
cirrhosis and ascites detectable on physical
examination. The diagnosis of cirrhosis was
proven by liver biopsy or based on clinical-
biochemical criteria (17). This group con-
sisted of 21 males and 12 females with a
mean age of 47 ± 12 years. The cirrhosis
etiology for this group was alcoholism (21
cases), viral infection (8 cases), non-alco-
holic steatohepatitis (2), α1 antitrypsin defi-
ciency (1), and cryptogenic cirrhosis (1).
Group 2. Twenty patients with neoplas-
tic ascites established by the presence of
neoplastic cells in the ascitic fluid and con-
firmed by the presence of peritoneal im-
plants during surgery or laparoscopy. This
group consisted of 9 men and 11 women
with a mean age of 60 ± 14 years. The sites of
primary tumor origin (all adenocarcinomas)
were: ovary (8), colon (4), stomach (4), blad-
der (2), pancreas (1), and uterus (1).
Exclusion criteria were ascitic fluid with
cellularity above 250 PMN/mm3 or positive
ascitic fluid culture, systemic infectious pro-
cesses at present or in the last 3 months
before inclusion in the study, patients who
had been previously treated or were cur-
rently being treated with chemotherapy or
radiotherapy, macroscopically hemorrhagic
ascitic fluid, suspicion of peritoneal tuber-
culosis based on laparoscopic findings or
ascites cellularity.
All patients were informed of the proce-
dures that they would be subjected to and
gave their written informed consent prior to
inclusion in the study. The study protocol
was approved by the Medical Ethics Com-
mittee of São Paulo Hospital, Universidade
Federal de São Paulo-Escola Paulista de
Medicina, São Paulo, SP, Brazil.
After selection, the patients were submit-
ted to abdominal paracentesis and blood was
collected from a peripheral vein for serum
evaluation. The samples were centrifuged
and divided into aliquots and a part was
stored frozen at -80ºC for laminin determi-
nation. Laboratory analysis of the ascitic
fluid included total and differential cell
counts, total protein and amylase determina-
tion, bacterial culture, and oncotic cytology.
Laminin was isolated from human pla-
centa as described by Schechter and Lopes
(18). The isolated protein was identified by
5% SDS-PAGE under reducing conditions
and protein concentration was estimated by
the method of Bradford (19-21). Total pro-
tein extraction from approximately 500 g of
fresh placental tissue yielded 31 mg laminin.
Antiserum was produced in female New
Zealand rabbits using monthly intramuscu-
lar injections of 100 µg purified laminin in
complete and incomplete Freund’s adjuvants
(22). Antilaminin titer was measured by en-
zyme-linked immunosorbent assay (ELISA)
using anti-rabbit IgG conjugated with per-
oxidase and o-phenylenediamine (23). For
the purification of the antibody obtained, 10
mg laminin was coupled to a CNBr-acti-
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vated Sepharose affinity column (Pharma-
cia, Uppsala, Sweden) and eluted with 0.1 M
glycine-HCl buffer, pH 3.0, containing 0.15
M NaCl. The final protein concentration
obtained was 852 µg antilaminin antibody/
ml. The conjugation of the secondary anti-
body with horseradish peroxidase was per-
formed by the method of Avrameas et al.
(24). The purified antibodies were used in an
immunohistochemical test with fresh sec-
tions of rat liver (25).
Laminin concentrations in serum and as-
citic fluid of subjects with peritoneal carci-
nomatosis and with liver cirrhosis, and in the
serum of healthy individuals were tested in
triplicate by ELISA. The serum-ascites lam-
inin gradient was calculated by subtracting
the ascites values from the serum concentra-
tion, while the serum/ascites ratio was ob-
tained by dividing the serum value by the
ascites concentration. The receiver operat-
ing characteristic (ROC) curve was used to
determined the relationship between serum
laminin levels and the diagnosis of neoplas-
tic ascites (26).
Statistical analysis was carried out by
Kruskal-Wallis analysis of variance comple-
mented by Dunn’s test and Pearson’s linear
correlation coefficient (27).
Results
The isolated human laminin was charac-
terized by SDS-PAGE under reducing con-
ditions (Figure 1) and by rat liver immuno-
histochemistry (Figure 2). The electropho-
retic profile, purity grade and immunohisto-
chemical results agreed with those reported
in the literature (25-29).
Serum and ascites laminin concentrations
found in the different groups studied are
shown in Table 1. The mean serum laminin
values were significantly higher in patients
with carcinomatosis and cirrhosis than in
individuals from the control group. Further-
more, the values obtained for the ascitic
fluid were statistically higher in patients with
carcinomatosis than in patients with cirrhosis.
The values of the serum-ascites gradient
(0.5 ± 0.34 in the cirrhotic group vs 0.5 ±
0.12 in the neoplastic group, means ± SD, P
= 1.00) and the serum/ascites laminin ratio
(1.35 ± 0.29 vs 1.21 ± 0.20, respectively, P =
0.065) did not differ between the two groups
(Figure 3). A highly significant correlation
was observed between laminin concentra-
tions in serum and in ascites of the patients
studied (r = 0.93, P < 0.0001; Figure 4).
ROC curve analysis showed that the area
under the curve of serum laminin was 0.967
(0.927-1.008 95% CI, P < 0.01). For serum
Figure 2. Photomicrograph
showing immunohistochemis-
try of rat liver sections. The ex-
pression of laminin detected by
anti-laminin antibodies is shown
in the portal spaces around the
biliary canaliculi, blood and lym-
phatic vessels. Magnification,
400X.
Table 1. Serum and ascites laminin concentrations in patients with cirrhosis and
neoplastic ascites and in control subjects.
Control subjects Cirrhotic patients Neoplastic patients
(N = 25) (N = 33) (N = 20)
Laminin in serum 0.183 ± 0.06 2.1 ± 0.4 3.3 ± 0.5
Laminin in ascites 1.6 ± 0.4 2.8 ± 0.5
Data are reported as means ± SD.
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Figure 1. Electrophoresis of lam-
inin in 5% polyacrylamide gel
(SDS-PAGE). Samples with mo-
lecular weight standards and
laminin purified (20 µg/ml) from
human placenta were applied.
Protein bands were visualized
by Coomassie brilliant blue
staining. A = Molecular weight
standard (Bio-Rad, Hercules,
CA, USA); B = human laminin
(HLN, arrow) under reduced
conditions. M = subunit of lami-
nin.
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first reported by Gressner and Tittor (4),
who attributed this increase to capillarization
of hepatic sinusoids, since laminin levels
were correlated with the portal pressure val-
ues of their patients. These findings were
confirmed by others (6,7) and were observed
in non-cirrhotic patients with portal hyper-
tension (4,5). As mentioned before, increases
in serum laminin levels are due to the forma-
tion of basement membranes in the hepatic
sinusoids. However, an additional effect due
to a lack of degradation of this protein by
liver endothelial cells cannot be ruled out
(30). On the other hand, the increased serum
laminin concentration has been related to
hepatic fibrosis and liver function in both
human and experimental studies (4,7,31-34).
Significantly higher serum laminin lev-
els were observed in patients with peritoneal
carcinomatosis (12-15,35,36). This elevated
serum concentration could be due to the
higher turnover of this glycoprotein in pa-
tients with advanced tumor lesions (12-15),
but could also be related to a greater release
of laminin molecule fragments, as reported
in neoplasms (37,38). Results obtained in
studies on neoplastic diseases have shown
that the growth of the tumor matrix and the
metastasizing process lead to an increase in
serum levels of basement membrane con-
stituents with tumor progression (13).
The mean laminin values in ascites of
patients with neoplasms were significantly
higher than in the cirrhosis group. However,
when the serum-ascites gradient and the se-
rum/ascites ratio of the studied groups were
analyzed, no significant differences could be
observed between them, suggesting that these
values were interdependent. This finding is
contrary to that reported by Byers et al. (39),
who found increases in laminin values in
ascites, but not in blood of patients with
ovarian tumors. In the present study, the
serum laminin values were higher than those
found in the ascitic fluid in every patient.
Furthermore, the lack of any significant dif-
ferences in the serum-ascites gradient and in
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Figure 3. Serum-ascites laminin ratio and gradient for cirrhotic patients and patients with
neoplasia. Mean serum-ascites laminin gradient (= serum - ascites laminin concentration)
and the ratio (= serum/ascites laminin concentration) did not differ between the groups
with benign (cirrhotic, N = 33) and neoplastic ascites (N = 20).
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Figure 4. Correlation between serum and ascites laminin values in the group with neoplasia
(N = 20) and the cirrhotic group (N = 33) calculated by Pearson’s correlation coefficient (r =
0.93; P < 0.0001).
laminin values higher than 2.25 µg/ml, the
diagnostic sensitivity was 100% and the
specificity 73%.
Discussion
We describe here an uptake assay that
utilizes a peroxidase-coupled double anti-
body system. This test is simple, quick and
reproducible and is able to measure laminin
levels in serum and ascites. Contrary to what
was observed by Smith and Bentsen (16), the
response of the test was linear for laminin
determination.
Increased serum laminin concentration
in patients with chronic liver diseases was
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the serum/ascites ratio, as well as the highly
significant correlation between laminin lev-
els in ascites and serum, clearly suggest that
the circulating levels of this glycoprotein are
the main determinant factor for the laminin
levels in ascites.
On the other hand, a high correlation
between serum and ascites laminin values
provides further evidence of the specificity
of the isolated antibody. Using the ROC
curves, we could define a cut-off value for
serum laminin to differentiate malignant from
benign (cirrhotic) ascites. The diagnostic
performance of serum laminin showed a sen-
sitivity of 100% and a specificity of 73% for
the diagnosis of neoplastic ascites.
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